Payment overview · 2025
General Payments
$1,684.33
42 reported records · 16 companies
Healthcare provider profile · identity verified
Grace Li
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · BROOKLYN, NY · NPI 1235711847
Verified facts
What the public records show
CMS Open Payments records show Grace Li received $1,684.33 in general payments during 2025 across 42 reported records.
Amgen Inc. accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Linzess, Nexletol, Shingrix, Trelegy Ellipta, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nexletol by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexlizet by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $363.16 | 21.6% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $317.74 | 18.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $206.55 | 12.3% | 10 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $175.00 | 10.4% | 4 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $156.66 | 9.3% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $143.70 | 8.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $77.91 | 4.6% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.59 | 2.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.27 | 1.9% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $27.38 | 1.6% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $25.80 | 1.5% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $25.00 | 1.5% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $21.98 | 1.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.88 | 1.3% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $21.88 | 1.3% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $20.83 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,652.06 | 41 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $351.79 | 7 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $175.00 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $164.62 | 8 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $156.66 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $143.70 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $77.91 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $67.74 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.59 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $41.93 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.27 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $25.80 | 1 | 2025 |
Source payment records
|
|||||
| Binosto Normalized: binosto |
Drug | Radius Health, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $21.88 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $11.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 35 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 136 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 53 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 48 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 76 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
35 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
110 | 23 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
36 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
136 | 49 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
81 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
48 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
76 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1069 | 278 |
| Vascepa | Icosapent Ethyl | 944 | 232 |
| Losartan Potassium | Losartan Potassium | 760 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 736 | 203 |
| Diclofenac Epolamine | Diclofenac Epolamine | 521 | 127 |
| Simvastatin | Simvastatin | 494 | 124 |
| Metformin Hcl | Metformin Hcl | 470 | 106 |
| Donepezil Hcl | Donepezil Hcl | 454 | 110 |
| Tamsulosin Hcl | Tamsulosin Hcl | 452 | 122 |
| Omeprazole | Omeprazole | 437 | 155 |
| Fluticasone Propionate | Fluticasone Propionate | 356 | 130 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 352 | 108 |
| Meclizine Hcl | Meclizine Hcl | 317 | 141 |
| Meloxicam | Meloxicam | 286 | 164 |
| Finasteride | Finasteride | 283 | 76 |
| Alendronate Sodium | Alendronate Sodium | 274 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 266 | 73 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 231 | 76 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 229 | 64 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 219 | 88 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 209 | 60 |
| Montelukast Sodium | Montelukast Sodium | 208 | 55 |
| Gabapentin | Gabapentin | 198 | 68 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 195 | 70 |
| Glipizide Er | Glipizide | 194 | 55 |
| Metformin Hcl Er | Metformin Hcl | 177 | 48 |
| Lisinopril | Lisinopril | 169 | 50 |
| Mirtazapine | Mirtazapine | 153 | 59 |
| Ammonium Lactate | Ammonium Lactate | 151 | 62 |
| Diclofenac Sodium | Diclofenac Sodium | 147 | 73 |
| Trazodone Hcl | Trazodone Hcl | 145 | 49 |
| Raloxifene Hcl | Raloxifene Hcl | 143 | 39 |
| Januvia | Sitagliptin Phosphate | 142 | 34 |
| Farxiga | Dapagliflozin Propanediol | 136 | 49 |
| Famotidine | Famotidine | 135 | 49 |
| Jardiance | Empagliflozin | 132 | 41 |
| Ibuprofen | Ibuprofen | 129 | 91 |
| Halobetasol Propionate | Halobetasol Propionate | 128 | 70 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 120 | 40 |
| Allopurinol | Allopurinol | 118 | 25 |
| Clobetasol Propionate | Clobetasol Propionate | 114 | 57 |
| Azelastine Hcl | Azelastine Hcl | 112 | 39 |
| Synthroid | Levothyroxine Sodium | 110 | 23 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 105 | 37 |
| Fenofibrate | Fenofibrate,micronized | 101 | 20 |
| Bepotastine Besilate | Bepotastine Besilate | 99 | 31 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 97 | 32 |
| Mometasone Furoate | Mometasone Furoate | 97 | 47 |
| Amoxicillin | Amoxicillin | 94 | 81 |
| Icosapent Ethyl | Icosapent Ethyl | 89 | 36 |
| Vemlidy | Tenofovir Alafenamide | 81 | 16 |
| Colchicine | Colchicine | 80 | 33 |
| Celecoxib | Celecoxib | 77 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 76 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 76 | 18 |
| Fluocinonide | Fluocinonide | 73 | 34 |
| Hydrocortisone | Hydrocortisone | 72 | 32 |
| Atenolol | Atenolol | 71 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 17 |
| Procto-Med Hc | Hydrocortisone | 58 | 18 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 57 | 18 |
| Enalapril Maleate | Enalapril Maleate | 57 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 57 | 21 |
| Baclofen | Baclofen | 56 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 21 |
| Azithromycin | Azithromycin | 55 | 49 |
| Fenofibrate | Fenofibrate | 54 | 16 |
| Linzess | Linaclotide | 53 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 53 | 23 |
| Folic Acid | Folic Acid | 51 | 23 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 51 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 49 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 48 | 24 |
| Carvedilol | Carvedilol | 47 | 14 |
| Eliquis | Apixaban | 47 | 14 |
| Ketoconazole | Ketoconazole | 47 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 46 | 39 |
| Dexlansoprazole Dr | Dexlansoprazole | 46 | 14 |
| Loperamide | Loperamide Hcl | 46 | 31 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | 15 |
| Rybelsus | Semaglutide | 41 | 11 |
| Xarelto | Rivaroxaban | 40 | 14 |
| Mupirocin | Mupirocin | 38 | 22 |
| Proctozone-Hc | Hydrocortisone | 38 | suppressed |
| Furosemide | Furosemide | 36 | 16 |
| Prolia | Denosumab | 36 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Creon | Lipase/Protease/Amylase | 35 | 12 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 35 | 13 |
| Ezetimibe | Ezetimibe | 33 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | 14 |
| Synjardy | Empagliflozin/Metformin Hcl | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 31 | suppressed |
| Naproxen | Naproxen | 31 | 16 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 31 | suppressed |
| Clotrimazole | Clotrimazole | 30 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Nexium | Esomeprazole Magnesium | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Dutasteride | Dutasteride | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 27 | suppressed |
| Roflumilast | Roflumilast | 27 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 26 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 25 | 11 |
| Glipizide | Glipizide | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 17 |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 20 | suppressed |
| Rivastigmine | Rivastigmine | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Nexletol | Bempedoic Acid | 19 | suppressed |
| Ciclopirox | Ciclopirox | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Flector | Diclofenac Epolamine | 17 | suppressed |
| Lactulose | Lactulose | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Livalo | Pitavastatin Calcium | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 11 |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 13 |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Entecavir | Entecavir | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Xifaxan | Rifaximin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,684.33 · 42 records | Amgen Inc. | AREXVY, ARTIX MT, Arikayce, BREZTRI, Binosto, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, LINZESS, NEXLETOL, Ohtuvayre, Ozempic, REPATHA, SAPIEN 3 Ultra RESILIA, SHINGRIX, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TRELEGY ELLIPTA, Tymlos, XIFAXAN | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error